To include your compound in the COVID-19 Resource Center, submit it here.

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

Targeted degrader company Arvinas takes hit on updated proof of concept data
Arvinas Inc. (NASDAQ:ARVN) shed nearly $500 million in market cap Friday after updated Phase I/II data showed no new responses among 12 additional patients dosed with ARV-110 at 140 mg

Read the full 411 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE